Home > Healthcare > Biotechnology > Bioservices > Personalized Medicine Biomarkers Market

Personalized Medicine Biomarkers Market Share

Report ID: GMI12082
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Personalized Medicine Biomarkers Market Share

The market is characterized by intense competition, driven by increasing demand for precision healthcare and advancements in biomarker-based diagnostics. Leading biotechnology and pharmaceutical companies hold significant market shares due to comprehensive biomarker portfolios and cutting-edge therapeutic solutions tailored to specific patient needs. Strategic initiatives such as mergers, acquisitions, and partnerships bolster their market presence, enabling expansion across diverse therapeutic areas, including oncology, cardiology, and neurology. Continuous investment in research and development allows these companies to capture new segments, meet growing demand for targeted therapies and diagnostics, and strengthen their global influence within the personalized medicine landscape.

Personalized Medicine Biomarkers Market Companies

Major players operating in the personalized medicine biomarkers industry are:

Abbott Laboratories
Bio-Rad Laboratories
Danaher
EKF Diagnostics Holdings
F. Hoffmann-La Roche
Illumina
Lifesign
Merck
Myriad Genetics
QIAGEN
Signosis
Singulex
Thermo Fisher Scientific

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global personalized medicine biomarkers industry was valued at USD 15.9 billion in 2023 and is estimated to grow at a CAGR of over 15.1% from 2024 to 2032, driven by the rising incidence of chronic diseases and advancements in genomics and proteomics.

The genomic biomarkers segment dominated the market with USD 6.6 billion in 2023, playing a pivotal role in disease detection, risk assessment, and treatment optimization.

U.S. personalized medicine biomarkers industry is expected to grow at a 15% CAGR, reaching USD 21.1 billion by 2032, led by advanced healthcare infrastructure and substantial R&D investments.

Key players in the industry include Abbott Laboratories, Bio-Rad Laboratories, Danaher, EKF Diagnostics Holdings, F. Hoffmann-La Roche, Illumina, Lifesign, Merck, Myriad Genetics, QIAGEN, Signosis, and Singulex.